RxDoctor Payments Data

Tri le, MD

Hematology & Oncology · Bedford, TXNPI 1609286756

Payments from drug & device makers

$3,653in general payments, 2019–2025

Across 88 payments — averaging $41.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Incyte Corporation$169
  • AstraZeneca$166
  • Gilead$164
  • Bristol Myers Squibb$137
  • GSK$116
  • plus $786 from 22 others

What the payments were for

  • Food & beverage$1,42539%
  • Education$1995%
  • Other$2,03056%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,653 in reported general payments places this provider in the 35th percentile of 838 hematology & oncology providers in Texas.

See all hematology & oncology providers in Texas

Medicare billing

Part B allowed, 2024
$2,431,640
Medicare patients
491
Services billed
90,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide28$623,004
BrukinsaZanubrutinib33$481,500
RevlimidLenalidomide20$343,608
Lenalidomide20$287,262
JakafiRuxolitinib Phosphate13$218,949
TagrissoOsimertinib Mesylate14$214,800
VenclextaVenetoclax12$186,388
PromactaEltrombopag Olamine12$142,539
EliquisApixaban122$140,298
CabometyxCabozantinib S-Malate12$138,270
XareltoRivaroxaban18$26,086
Enoxaparin Sodium22$5,501
Hydroxyurea36$1,191
Anastrozole55$721
Acyclovir35$524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$67$623,00428 claims
Bristol Myers SquibbRevlimid$137$343,60820 claims
Incyte CorporationJakafi$169$218,94913 claims
AstraZenecaTagrisso$166$214,80014 claims
AbbVieVenclexta$53$186,38812 claims
NovartisPromacta$2,114$142,53912 claims
PfizerEliquis$39$140,298122 claims
Exelixis Inc.Cabometyx$24$138,27012 claims
Johnson & JohnsonXarelto$47$26,08618 claims
Lilly USA, LLCOlanzapine$67$36637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 838 hematology & oncology providers in Texas.

Other hematology & oncology in Bedford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →